NeoGemTax: Gemcitabine and Docetaxel as Neoadjuvant Treatment for Locally Advanced Nonmetastasized Pancreatic Cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2011-04-27

AUTHORS

Klaus Sahora, Irene Kuehrer, Martin Schindl, Claus Koelblinger, Peter Goetzinger, Michael Gnant

ABSTRACT

BackgroundAbout 30% of patients with pancreatic cancer suffer from locally advanced nonmetastatic carcinoma at the time of diagnosis. We conducted a prospective phase II clinical trial using neoadjuvant chemotherapy, consisting of gemcitabine and docetaxel, to assess the rate of complete radical resection and overall survival.MethodsGemcitabine (900 mg/m2) and docetaxel (35 mg/m2) were given on days 1, 8, and 15 of a 28-day cycle. Two cycles were administered for a preoperative treatment duration of 8 weeks. Patients experiencing tumor regression or stable disease and improved performance status subsequently underwent surgical exploration and pancreatic resection, if feasible. All patients were followed postoperatively to assess long-term survival.ResultsA total of 25 patients were eligible and included in the intent-to-treat and evaluable population. Thirteen patients had unresectable disease at inclusion and 12 patients had borderline resectable pancreatic cancer. Finally, 8 of 25 (32%) patients underwent resection after neoadjuvant chemotherapy; 7 (87%) of these patients had R0 resection. The median overall survival of patients who underwent resection was 16 months (95% confidence interval [CI], 8–24 months) compared to 12 months (95% CI, 8–16 months) for those without resection (p = 0.276). The median recurrence-free survival rate after resection was 12 months (95% CI, 2–21 months).ConclusionsNeoGemTax was safe and resection was feasible in a number of patients after systemic neoadjuvant treatment. Further randomized clinical trials are needed to identify novel multimodal regimens that would be able to increase the percentage of patients undergoing curative pancreatic cancer surgery despite advanced tumor stage at the time of diagnosis. More... »

PAGES

1580-1589

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00268-011-1113-8

DOI

http://dx.doi.org/10.1007/s00268-011-1113-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1001068936

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/21523499


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adenocarcinoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deoxycytidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Docetaxel", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoadjuvant Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pancreatic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Taxoids", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria", 
          "id": "http://www.grid.ac/institutes/grid.22937.3d", 
          "name": [
            "Department of Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sahora", 
        "givenName": "Klaus", 
        "id": "sg:person.01346566072.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346566072.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria", 
          "id": "http://www.grid.ac/institutes/grid.22937.3d", 
          "name": [
            "Department of Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kuehrer", 
        "givenName": "Irene", 
        "id": "sg:person.01312145545.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01312145545.83"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria", 
          "id": "http://www.grid.ac/institutes/grid.22937.3d", 
          "name": [
            "Department of Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schindl", 
        "givenName": "Martin", 
        "id": "sg:person.0603017413.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603017413.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria", 
          "id": "http://www.grid.ac/institutes/grid.22937.3d", 
          "name": [
            "Department of Radiology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Koelblinger", 
        "givenName": "Claus", 
        "id": "sg:person.01370076117.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01370076117.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria", 
          "id": "http://www.grid.ac/institutes/grid.22937.3d", 
          "name": [
            "Department of Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Goetzinger", 
        "givenName": "Peter", 
        "id": "sg:person.01353346274.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01353346274.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria", 
          "id": "http://www.grid.ac/institutes/grid.22937.3d", 
          "name": [
            "Department of Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gnant", 
        "givenName": "Michael", 
        "id": "sg:person.01112754113.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01112754113.07"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/978-1-4757-3656-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032089040", 
          "https://doi.org/10.1007/978-1-4757-3656-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11605-007-0296-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018168659", 
          "https://doi.org/10.1007/s11605-007-0296-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-009-0995-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021635668", 
          "https://doi.org/10.1007/s00280-009-0995-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1245/s10434-006-9032-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019846526", 
          "https://doi.org/10.1245/s10434-006-9032-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02469407", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007111819", 
          "https://doi.org/10.1007/bf02469407"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6603719", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019012220", 
          "https://doi.org/10.1038/sj.bjc.6603719"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1245/s10434-009-0408-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051621519", 
          "https://doi.org/10.1245/s10434-009-0408-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1016/s1091-255x(98)80008-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015563431", 
          "https://doi.org/10.1016/s1091-255x(98)80008-5"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2011-04-27", 
    "datePublishedReg": "2011-04-27", 
    "description": "BackgroundAbout 30% of patients with pancreatic cancer suffer from locally advanced nonmetastatic carcinoma at the time of diagnosis. We conducted a prospective phase II clinical trial using neoadjuvant chemotherapy, consisting of gemcitabine and docetaxel, to assess the rate of complete radical resection and overall survival.MethodsGemcitabine (900\u00a0mg/m2) and docetaxel (35\u00a0mg/m2) were given on days 1, 8, and 15 of a 28-day cycle. Two cycles were administered for a preoperative treatment duration of 8\u00a0weeks. Patients experiencing tumor regression or stable disease and improved performance status subsequently underwent surgical exploration and pancreatic resection, if feasible. All patients were followed postoperatively to assess long-term survival.ResultsA total of 25 patients were eligible and included in the intent-to-treat and evaluable population. Thirteen patients had unresectable disease at inclusion and 12 patients had borderline resectable pancreatic cancer. Finally, 8 of 25 (32%) patients underwent resection after neoadjuvant chemotherapy; 7 (87%) of these patients had R0 resection. The median overall survival of patients who underwent resection was 16\u00a0months (95% confidence interval [CI], 8\u201324\u00a0months) compared to 12\u00a0months (95% CI, 8\u201316\u00a0months) for those without resection (p\u00a0=\u00a00.276). The median recurrence-free survival rate after resection was 12\u00a0months (95% CI, 2\u201321\u00a0months).ConclusionsNeoGemTax was safe and resection was feasible in a number of patients after systemic neoadjuvant treatment. Further randomized clinical trials are needed to identify novel multimodal regimens that would be able to increase the percentage of patients undergoing curative pancreatic cancer surgery despite advanced tumor stage at the time of diagnosis.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00268-011-1113-8", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1086446", 
        "issn": [
          "0364-2313", 
          "1432-2323"
        ], 
        "name": "World Journal of Surgery", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "7", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "35"
      }
    ], 
    "keywords": [
      "time of diagnosis", 
      "pancreatic cancer", 
      "neoadjuvant treatment", 
      "neoadjuvant chemotherapy", 
      "overall survival", 
      "clinical trials", 
      "prospective phase II clinical trial", 
      "median recurrence-free survival rate", 
      "borderline resectable pancreatic cancer", 
      "recurrence-free survival rates", 
      "phase II clinical trial", 
      "improved performance status", 
      "resectable pancreatic cancer", 
      "median overall survival", 
      "percentage of patients", 
      "pancreatic cancer surgery", 
      "number of patients", 
      "advanced tumor stage", 
      "complete radical resection", 
      "II clinical trials", 
      "long-term survival", 
      "stable disease", 
      "evaluable population", 
      "unresectable disease", 
      "R0 resection", 
      "performance status", 
      "pancreatic resection", 
      "radical resection", 
      "surgical exploration", 
      "multimodal regimens", 
      "cancer surgery", 
      "tumor stage", 
      "tumor regression", 
      "nonmetastatic carcinoma", 
      "ResultsA total", 
      "resection", 
      "patients", 
      "treatment duration", 
      "day 1", 
      "survival rate", 
      "docetaxel", 
      "BackgroundAbout 30", 
      "cancer", 
      "months", 
      "chemotherapy", 
      "gemcitabine", 
      "survival", 
      "disease", 
      "diagnosis", 
      "trials", 
      "treatment", 
      "MethodsGemcitabine", 
      "regimens", 
      "surgery", 
      "carcinoma", 
      "weeks", 
      "total", 
      "duration", 
      "treat", 
      "rate", 
      "status", 
      "regression", 
      "population", 
      "percentage", 
      "time", 
      "intent", 
      "stage", 
      "cycle", 
      "inclusion", 
      "number", 
      "exploration"
    ], 
    "name": "NeoGemTax: Gemcitabine and Docetaxel as Neoadjuvant Treatment for Locally Advanced Nonmetastasized Pancreatic Cancer", 
    "pagination": "1580-1589", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1001068936"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00268-011-1113-8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "21523499"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00268-011-1113-8", 
      "https://app.dimensions.ai/details/publication/pub.1001068936"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:27", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_538.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00268-011-1113-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00268-011-1113-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00268-011-1113-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00268-011-1113-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00268-011-1113-8'


 

This table displays all metadata directly associated to this object as RDF triples.

262 TRIPLES      22 PREDICATES      120 URIs      104 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00268-011-1113-8 schema:about N00b7b841458e4c25a4002a342424c003
2 N00df5f5acb0d4b90a0aab5c0ef46369d
3 N2b6cc7655be9455abbf3b3ca546071b5
4 N4806102e8cf14227b2a0b3305adf0d95
5 N55c23de302024bf9ba73a3b1410ea89e
6 N5f2663da85434784a1442259e7d5ee2e
7 N6d21bdf78fe246939bf6ef720370a995
8 N81113c2b3fda421b816f7ec498f25cf8
9 Na7d976c3e14a4d05bd822dd3ff3c1b3c
10 Nab5c43cd86ff4d66aa547992c47c7ba9
11 Nb5c4c8fdff8842258234dc7e7791ac6b
12 Nd282337fcb084805a9a01552644ca701
13 Ne45c157563344a329312ece83c74be51
14 Ne8b867fae11c499391f3c2eb69b5c3f4
15 Nf32d4aa0be0341f79b918d4b8457d32a
16 anzsrc-for:11
17 anzsrc-for:1112
18 schema:author Nb4f35e3f4b7f403fae1a0284ead5b52c
19 schema:citation sg:pub.10.1007/978-1-4757-3656-4
20 sg:pub.10.1007/bf02469407
21 sg:pub.10.1007/s00280-009-0995-8
22 sg:pub.10.1007/s11605-007-0296-7
23 sg:pub.10.1016/s1091-255x(98)80008-5
24 sg:pub.10.1038/sj.bjc.6603719
25 sg:pub.10.1245/s10434-006-9032-x
26 sg:pub.10.1245/s10434-009-0408-6
27 schema:datePublished 2011-04-27
28 schema:datePublishedReg 2011-04-27
29 schema:description BackgroundAbout 30% of patients with pancreatic cancer suffer from locally advanced nonmetastatic carcinoma at the time of diagnosis. We conducted a prospective phase II clinical trial using neoadjuvant chemotherapy, consisting of gemcitabine and docetaxel, to assess the rate of complete radical resection and overall survival.MethodsGemcitabine (900 mg/m2) and docetaxel (35 mg/m2) were given on days 1, 8, and 15 of a 28-day cycle. Two cycles were administered for a preoperative treatment duration of 8 weeks. Patients experiencing tumor regression or stable disease and improved performance status subsequently underwent surgical exploration and pancreatic resection, if feasible. All patients were followed postoperatively to assess long-term survival.ResultsA total of 25 patients were eligible and included in the intent-to-treat and evaluable population. Thirteen patients had unresectable disease at inclusion and 12 patients had borderline resectable pancreatic cancer. Finally, 8 of 25 (32%) patients underwent resection after neoadjuvant chemotherapy; 7 (87%) of these patients had R0 resection. The median overall survival of patients who underwent resection was 16 months (95% confidence interval [CI], 8–24 months) compared to 12 months (95% CI, 8–16 months) for those without resection (p = 0.276). The median recurrence-free survival rate after resection was 12 months (95% CI, 2–21 months).ConclusionsNeoGemTax was safe and resection was feasible in a number of patients after systemic neoadjuvant treatment. Further randomized clinical trials are needed to identify novel multimodal regimens that would be able to increase the percentage of patients undergoing curative pancreatic cancer surgery despite advanced tumor stage at the time of diagnosis.
30 schema:genre article
31 schema:inLanguage en
32 schema:isAccessibleForFree false
33 schema:isPartOf N26ebfb7e6b30415997c69984e1c60b81
34 Nda9ebdd641e3432caf12ae4085e41bd9
35 sg:journal.1086446
36 schema:keywords BackgroundAbout 30
37 II clinical trials
38 MethodsGemcitabine
39 R0 resection
40 ResultsA total
41 advanced tumor stage
42 borderline resectable pancreatic cancer
43 cancer
44 cancer surgery
45 carcinoma
46 chemotherapy
47 clinical trials
48 complete radical resection
49 cycle
50 day 1
51 diagnosis
52 disease
53 docetaxel
54 duration
55 evaluable population
56 exploration
57 gemcitabine
58 improved performance status
59 inclusion
60 intent
61 long-term survival
62 median overall survival
63 median recurrence-free survival rate
64 months
65 multimodal regimens
66 neoadjuvant chemotherapy
67 neoadjuvant treatment
68 nonmetastatic carcinoma
69 number
70 number of patients
71 overall survival
72 pancreatic cancer
73 pancreatic cancer surgery
74 pancreatic resection
75 patients
76 percentage
77 percentage of patients
78 performance status
79 phase II clinical trial
80 population
81 prospective phase II clinical trial
82 radical resection
83 rate
84 recurrence-free survival rates
85 regimens
86 regression
87 resectable pancreatic cancer
88 resection
89 stable disease
90 stage
91 status
92 surgery
93 surgical exploration
94 survival
95 survival rate
96 time
97 time of diagnosis
98 total
99 treat
100 treatment
101 treatment duration
102 trials
103 tumor regression
104 tumor stage
105 unresectable disease
106 weeks
107 schema:name NeoGemTax: Gemcitabine and Docetaxel as Neoadjuvant Treatment for Locally Advanced Nonmetastasized Pancreatic Cancer
108 schema:pagination 1580-1589
109 schema:productId Na426ec9cc1854b17b550610955921768
110 Nac16c0af5a604fa49c21100c50b339f4
111 Nf65d90ceb3094aed97ea44fa7352f801
112 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001068936
113 https://doi.org/10.1007/s00268-011-1113-8
114 schema:sdDatePublished 2022-05-20T07:27
115 schema:sdLicense https://scigraph.springernature.com/explorer/license/
116 schema:sdPublisher N2cffe06e1f2d4f678ac8747f1b2a3067
117 schema:url https://doi.org/10.1007/s00268-011-1113-8
118 sgo:license sg:explorer/license/
119 sgo:sdDataset articles
120 rdf:type schema:ScholarlyArticle
121 N00b7b841458e4c25a4002a342424c003 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Pancreatic Neoplasms
123 rdf:type schema:DefinedTerm
124 N00df5f5acb0d4b90a0aab5c0ef46369d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Prospective Studies
126 rdf:type schema:DefinedTerm
127 N1c6f46713bba4127ac54bbf9f52dc3f1 rdf:first sg:person.01353346274.48
128 rdf:rest N9d7f8d511e0546b496871afd6854176f
129 N26ebfb7e6b30415997c69984e1c60b81 schema:volumeNumber 35
130 rdf:type schema:PublicationVolume
131 N2b6cc7655be9455abbf3b3ca546071b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Neoadjuvant Therapy
133 rdf:type schema:DefinedTerm
134 N2cffe06e1f2d4f678ac8747f1b2a3067 schema:name Springer Nature - SN SciGraph project
135 rdf:type schema:Organization
136 N3b94da781e86492dbdf048670e535fdc rdf:first sg:person.01370076117.00
137 rdf:rest N1c6f46713bba4127ac54bbf9f52dc3f1
138 N4806102e8cf14227b2a0b3305adf0d95 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Middle Aged
140 rdf:type schema:DefinedTerm
141 N55c23de302024bf9ba73a3b1410ea89e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Aged
143 rdf:type schema:DefinedTerm
144 N5f2663da85434784a1442259e7d5ee2e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Antineoplastic Combined Chemotherapy Protocols
146 rdf:type schema:DefinedTerm
147 N651aa399103d4fccb87e69024e04167f rdf:first sg:person.01312145545.83
148 rdf:rest N99147d340a414547ad9311720dfaf8d7
149 N6d21bdf78fe246939bf6ef720370a995 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Docetaxel
151 rdf:type schema:DefinedTerm
152 N81113c2b3fda421b816f7ec498f25cf8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Aged, 80 and over
154 rdf:type schema:DefinedTerm
155 N99147d340a414547ad9311720dfaf8d7 rdf:first sg:person.0603017413.32
156 rdf:rest N3b94da781e86492dbdf048670e535fdc
157 N9d7f8d511e0546b496871afd6854176f rdf:first sg:person.01112754113.07
158 rdf:rest rdf:nil
159 Na426ec9cc1854b17b550610955921768 schema:name doi
160 schema:value 10.1007/s00268-011-1113-8
161 rdf:type schema:PropertyValue
162 Na7d976c3e14a4d05bd822dd3ff3c1b3c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Male
164 rdf:type schema:DefinedTerm
165 Nab5c43cd86ff4d66aa547992c47c7ba9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Humans
167 rdf:type schema:DefinedTerm
168 Nac16c0af5a604fa49c21100c50b339f4 schema:name pubmed_id
169 schema:value 21523499
170 rdf:type schema:PropertyValue
171 Nb4f35e3f4b7f403fae1a0284ead5b52c rdf:first sg:person.01346566072.85
172 rdf:rest N651aa399103d4fccb87e69024e04167f
173 Nb5c4c8fdff8842258234dc7e7791ac6b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Female
175 rdf:type schema:DefinedTerm
176 Nd282337fcb084805a9a01552644ca701 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Taxoids
178 rdf:type schema:DefinedTerm
179 Nda9ebdd641e3432caf12ae4085e41bd9 schema:issueNumber 7
180 rdf:type schema:PublicationIssue
181 Ne45c157563344a329312ece83c74be51 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Deoxycytidine
183 rdf:type schema:DefinedTerm
184 Ne8b867fae11c499391f3c2eb69b5c3f4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Adenocarcinoma
186 rdf:type schema:DefinedTerm
187 Nf32d4aa0be0341f79b918d4b8457d32a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Neoplasm Staging
189 rdf:type schema:DefinedTerm
190 Nf65d90ceb3094aed97ea44fa7352f801 schema:name dimensions_id
191 schema:value pub.1001068936
192 rdf:type schema:PropertyValue
193 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
194 schema:name Medical and Health Sciences
195 rdf:type schema:DefinedTerm
196 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
197 schema:name Oncology and Carcinogenesis
198 rdf:type schema:DefinedTerm
199 sg:journal.1086446 schema:issn 0364-2313
200 1432-2323
201 schema:name World Journal of Surgery
202 schema:publisher Springer Nature
203 rdf:type schema:Periodical
204 sg:person.01112754113.07 schema:affiliation grid-institutes:grid.22937.3d
205 schema:familyName Gnant
206 schema:givenName Michael
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01112754113.07
208 rdf:type schema:Person
209 sg:person.01312145545.83 schema:affiliation grid-institutes:grid.22937.3d
210 schema:familyName Kuehrer
211 schema:givenName Irene
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01312145545.83
213 rdf:type schema:Person
214 sg:person.01346566072.85 schema:affiliation grid-institutes:grid.22937.3d
215 schema:familyName Sahora
216 schema:givenName Klaus
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346566072.85
218 rdf:type schema:Person
219 sg:person.01353346274.48 schema:affiliation grid-institutes:grid.22937.3d
220 schema:familyName Goetzinger
221 schema:givenName Peter
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01353346274.48
223 rdf:type schema:Person
224 sg:person.01370076117.00 schema:affiliation grid-institutes:grid.22937.3d
225 schema:familyName Koelblinger
226 schema:givenName Claus
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01370076117.00
228 rdf:type schema:Person
229 sg:person.0603017413.32 schema:affiliation grid-institutes:grid.22937.3d
230 schema:familyName Schindl
231 schema:givenName Martin
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0603017413.32
233 rdf:type schema:Person
234 sg:pub.10.1007/978-1-4757-3656-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032089040
235 https://doi.org/10.1007/978-1-4757-3656-4
236 rdf:type schema:CreativeWork
237 sg:pub.10.1007/bf02469407 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007111819
238 https://doi.org/10.1007/bf02469407
239 rdf:type schema:CreativeWork
240 sg:pub.10.1007/s00280-009-0995-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021635668
241 https://doi.org/10.1007/s00280-009-0995-8
242 rdf:type schema:CreativeWork
243 sg:pub.10.1007/s11605-007-0296-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018168659
244 https://doi.org/10.1007/s11605-007-0296-7
245 rdf:type schema:CreativeWork
246 sg:pub.10.1016/s1091-255x(98)80008-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015563431
247 https://doi.org/10.1016/s1091-255x(98)80008-5
248 rdf:type schema:CreativeWork
249 sg:pub.10.1038/sj.bjc.6603719 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019012220
250 https://doi.org/10.1038/sj.bjc.6603719
251 rdf:type schema:CreativeWork
252 sg:pub.10.1245/s10434-006-9032-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1019846526
253 https://doi.org/10.1245/s10434-006-9032-x
254 rdf:type schema:CreativeWork
255 sg:pub.10.1245/s10434-009-0408-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051621519
256 https://doi.org/10.1245/s10434-009-0408-6
257 rdf:type schema:CreativeWork
258 grid-institutes:grid.22937.3d schema:alternateName Department of Radiology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria
259 Department of Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria
260 schema:name Department of Radiology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria
261 Department of Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria
262 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...